Data collected from the International Severe Chronic Neutropenia Registry, based on a follow-up survey of 3,590 person-years, showed that after 10 years of treatment with G-CSF, the annual risk of MDS/AML was 2.3%. This evidence concerns the gene CSF3 and acute myeloid leukemia.